Company: ATHE
Filing Date: 2025-08-29
Form Type: 20-F
Source: 0001213900-25-082027
Chunk: 70

Company: ALTERITY THERAPEUTICS LTD
Filing Date: 2025-08-29
Form: 20-F
Item: Item 5
Chunk 70
---
 15, 2024, we filed a Prospectus Supplement relating to the offering of up to US$6,000,000 in ADSs with the SEC.

On July 18, 2024, 75,220,800 ordinary shares were issued under the ADS Sales Agreement, raising $366k net of security issuance costs.

On February 3, 2025, 164,242,200 ordinary shares were issued under the ADS Sales Agreement, raising $2,058k net of security issuance costs.

In February 2025, we received commitments for a capital raising of approximately $40 million by means of a two tranche placement (the Placement) of fully paid ordinary shares. For every three new shares issued, one free attaching option was issued. The number of securities issued to the Placement participants on February 17, 2025 (Tranche 1), April 4, 2025 (Tranche 2) and April 23,2025 (Options) pursuant to ASX Listing Rule 7.1, and which are within the volumes approved by shareholders at the EGM on March 31, 2025, are:

●   3,636,363,636 ordinary shares at A$0.011 (1.1 Australian cents) per share
                                  (ASX:ATH); and                             
-----------------------------------------------------------------------------

●   1,222,300,911 listed Long-Dated Options (each with an exercise price of A$0.028,
                      expiring on February 26, 2027) (ASX: ATHOA).                  
------------------------------------------------------------------------------------

On February 17, 2025, 1,165,841,830 ordinary shares were issued under Tranche 1 of the Placement, raising $12.028 million, net of security issuance costs.

On April 4, 2025, 2,470,521,806 ordinary shares were issued under Tranche 2 of the Placement, raising $25.474m net of security issuance costs.

 As of June 30, 2025, we had a total of 2,683.5 million unlisted and listed unexercised options outstanding. The options have exercise prices ranging from A$0.004 to A$0.09. If all unlisted options were exercised in full, we would receive consideration of A$52,792,222 in total.

From inception to June 30, 2025, our capital expenditures have totaled A$849,729,